TrialThe Lancet. Oncology2018

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.

Stephanie M de Boer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.